ORMP
NASDAQOramed Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$3.73+0.35 (+10.29%)
2026-03-052026-06-08
News · 26 weeks330%
2025-12-142026-06-07
Mix1390d
- Insider7(54%)
- SEC Filings3(23%)
- Other2(15%)
- M&A1(8%)
Latest news
25 items- SECSEC Form 10-Q filed by Oramed Pharmaceuticals Inc.10-Q - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
- SECSEC Form NT 10-Q filed by Oramed Pharmaceuticals Inc.NT 10-Q - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
- SECOramed Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
- INSIDERSEC Form 4 filed by Kidron Nadav4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERSEC Form 4 filed by Kidron Miriam4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- SECSEC Form 10-K filed by Oramed Pharmaceuticals Inc.10-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
- PRLifeward Successfully Closes on Strategic Partnership with OramedHUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed on the Company's previously announced strategic partnership agreement with Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). The transaction has positioned Lifeward as a diversified biomedical innovation company with an expected clear path to profitability. Lifeward acquired Oramed's clinical-stage Protein Oral Delivery (POD™) technology, adding exposure to a large, long-term biotech market opportunity
- INSIDERSEC Form 4 filed by Gabay Avraham4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERSEC Form 4 filed by Hexter Joshua4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERSEC Form 4 filed by Kidron Miriam4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERSEC Form 4 filed by Kidron Nadav4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERPresident and CEO Kidron Nadav gifted 100,000 shares, decreasing direct ownership by 3% to 3,255,238 units (SEC Form 4)4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- PRLifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical CompanyPositions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform's clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that its shareholders approved the issuances of ordinary shares of the Company in connection with closing of the Co
- SECOramed Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
- INSIDERPresident and CEO Kidron Nadav converted options into 109,000 shares, increasing direct ownership by 3% to 3,355,238 units (SEC Form 4)4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERChief Financial Officer Gabay Avraham converted options into 19,000 shares, increasing direct ownership by 3% to 649,256 units (SEC Form 4)4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERChief Scientific Officer Kidron Miriam converted options into 19,000 shares, increasing direct ownership by 1% to 1,448,664 units (SEC Form 4)4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERCOO & CBO Hexter Joshua converted options into 19,000 shares, increasing direct ownership by 2% to 1,064,495 units (SEC Form 4)4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERChief Scientific Officer Kidron Miriam gifted 86,166 shares, decreasing direct ownership by 6% to 1,343,498 units (SEC Form 4)4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- SECOramed Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
- PROramed and Lifeward Announce Strategic TransactionTransaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward while retaining management of clinical programOramed will receive 49.9% beneficial ownership interest in Lifeward, a revenue-generating medical robotics company, including warrantsMark Grant, Lifeward CEO, with 25+ years experience in the diabetes sector at Medtronic and Bristol Myers Squibb, to lead combined platformsIn addition, strategic investment by Oramed designed to bring Lifeward towards profitabilityLifeward's FDA-approved ReWalk® and AlterG® products generated $26 million in last four quartersNE
- SECOramed Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
- PROramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend PaymentsPayment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) today announced it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. This payment brings Oramed's current returns to $118 million on its original $99.5 million Scilex investment, with additional returns expected from the remaining convertible notes, warrants, and royalties. Oramed retains a $27 million note and a $12 million convertible note with Scilex, convert
- INSIDERDirector Reznick Yehuda was granted 36,250 shares, increasing direct ownership by 53% to 105,180 units (SEC Form 4)4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
- INSIDERPresident and CEO Kidron Nadav was granted 559,640 shares, increasing direct ownership by 21% to 3,246,238 units (SEC Form 4)4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
ORMP FAQ
6 questionsWhat does Oramed Pharmaceuticals Inc. do?
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral...Where does ORMP stock trade?
Oramed Pharmaceuticals Inc. (ORMP) is listed on NASDAQ.What sector and industry is ORMP in?
Oramed Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ORMP?
Oramed Pharmaceuticals Inc. has had 6 recent analyst actions on file. The most recent action was from Canaccord Genuity: Hold with a $300.00 price target on 2023-01-12.What companies are similar to ORMP?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ORMP side-by-side with any of them on Quantisnow.How can I track ORMP on Quantisnow?
Quantisnow aggregates Oramed Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ORMP to receive live email and push alerts on every new disclosure.